Esperion TherapeuticsNASDAQ: ESPR

ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.

ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives –

Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy rating for Esperion Therapeutics, Inc. based on current execution and expanding international scope.

Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough.

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.

– Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth –

Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates.